Patents by Inventor Timothy John Ritchie

Timothy John Ritchie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome
    Patent number: 11925632
    Abstract: The present invention relates to new agents useful for the prevention and/or treatment of GLUT1-DS and related methods using the same.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: March 12, 2024
    Assignee: GLIAPHARM SA
    Inventors: Pierre Magistretti, Sylvain Lengacher, Charles Finsterwald, Timothy John Ritchie
  • ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME
    Publication number: 20230102415
    Abstract: The present invention relates to new agents useful for the prevention and/or treatment of GLUT1-DS and related methods using the same.
    Type: Application
    Filed: December 29, 2020
    Publication date: March 30, 2023
    Inventors: PIERRE MAGISTRETTI, SYLVAIN LENGACHER, CHARLES FINSTERWALD, TIMOTHY JOHN RITCHIE
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20190083474
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 15, 2018
    Publication date: March 21, 2019
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20180078536
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 22, 2018
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
    Patent number: 9849117
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: December 26, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20170112814
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists
    Patent number: 9567343
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: February 14, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Substituted quinazolinones as vanilloid antagonists
    Patent number: 9102653
    Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 11, 2015
    Assignee: NOVARTIS AG
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20150183794
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 10, 2015
    Publication date: July 2, 2015
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists
    Patent number: 9012451
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: April 21, 2015
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie
  • QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS
    Publication number: 20140315932
    Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Applicant: NOVARTIS AG
    Inventors: Timothy John RITCHIE, Andrew James CULSHAW, Christopher Thomas BRAIN, Edward Karol DZIADULEWICZ, Terance William HART
  • Quinazolinone derivatives useful as vanilloid antagonists
    Patent number: 8809528
    Abstract: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: August 19, 2014
    Assignee: Novartis AG
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • Compounds
    Patent number: 8765743
    Abstract: The invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: July 1, 2014
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Benzpyrazol derivatives as inhibitors of PI3 kinases
    Patent number: 8658635
    Abstract: The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: February 25, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Compounds
    Patent number: 8536169
    Abstract: The invention is directed to certain novel compounds directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: September 17, 2013
    Assignee: Glaxo Group Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Joelle Le, Nigel James Parr, Timothy John Ritchie, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Novel Use
    Publication number: 20130165433
    Abstract: The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.
    Type: Application
    Filed: September 6, 2011
    Publication date: June 27, 2013
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Zoe Alicia Harrison, Katherine Louise Jones, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Christopher James Lunniss, Charlotte Jane Mitchell, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Juliet Kay Simpson, Christopher Alan Paul Smethurst, Yoshiaki Washio
  • Pyrazole derivatives used as CCR4 receptor antagonists
    Patent number: 8357716
    Abstract: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: January 22, 2013
    Assignee: Glaxo Group Limited
    Inventors: Heather Hobbs, Simon Teanby Hodgson, Yannick Maurice LaCroix, Deborah Needham, Nigel James Parr, Panayiotis Alexandrou Procopiou, Timothy John Ritchie, Michael David Woodrow
  • BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES
    Publication number: 20120245171
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Application
    Filed: December 3, 2010
    Publication date: September 27, 2012
    Applicant: GLAXO GROUP LIMITED
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Katherine Louise Jones, Paul Spencer Jones, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • NOVEL COMPOUNDS
    Publication number: 20120238559
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Application
    Filed: December 3, 2010
    Publication date: September 20, 2012
    Applicant: GLAXO GROUP LIMITED
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • INDAZOLE DERIVATIVES AS PI 3-KINASE
    Publication number: 20120238571
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Application
    Filed: December 3, 2010
    Publication date: September 20, 2012
    Applicant: Glaxo Group Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Katherine Louise Jones, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Christian Alan Paul Smethurst